| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15042 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-87 |
| filingDate |
2015-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f812d148aa3ea6f07ddd1d1cee85c4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5a18a188d08d7a2feace3108bb900a4 |
| publicationDate |
2020-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3750993-A1 |
| titleOfInvention |
Methods of improving vector transduction efficiency into t lymphocytes |
| abstract |
Provided herewith is a method of transducing a primary T lymphocyte, comprising:(i) contacting a primary T lymphocyte with a compound that is BX795 or 2-Aminopurine;(ii) contacting said primary T lymphocyte with a lentiviral vector or retroviral vector comprising a nucleic acid, wherein said nucleic acid encodes a chimeric antigen receptor (CAR) comprising an extracellular domain,wherein said contacting of said primary T lymphocyte with said compound occurs prior to the contacting of said primary T lymphocyte with said lentiviral vector or retroviral vector; andwherein said method further comprises contacting said primary T lymphocyte with an agent capable of stimulating a T cell receptor complex prior to contacting said primary T lymphocyte with said lentiviral vector or retroviral vector;wherein said agent is an antibody or antigen-binding fragment specifically binding to CD3 and/or CD28; andwhereby the nucleic acid is transduced into the T lymphocyte. |
| priorityDate |
2014-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |